Banca de DEFESA: NEY MOURA LEMOS PEREIRA

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : NEY MOURA LEMOS PEREIRA
DATE: 02/07/2021
TIME: 14:00
LOCAL: Videoconferencia
TITLE:

AVALIAÇÃO DAS CONCENTRAÇÕES SÉRICAS DE MAGNÉSIO DE
PACIENTES SUBMETIDOS A QUIMIOTERAPIA COM DERIVADOS
DE PLATINA EM ASSOCIAÇÃO COM INIBIDORES DE BOMBAS DE
PRÓTONS E SUA CORRELAÇÃO COM AS NEUROPATIAS.


KEY WORDS:

Platinum compounds; Proton pump inhibitors; Magnesium;


PAGES: 80
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUMMARY:

Platinum-based drugs are regularly prescribed in the treatment of cancer and, although
they are effective, their use is limited by serious side effects. Another group of drugs
used in cancer patients are proton pump inhibitors (PPIs) in order to prevent and treat
gastric reactions during cancer treatment. However, both drugs can cause
hypomagnesemia, by different mechanisms. The work aims to evaluate serum
magnesium concentrations in patients undergoing chemotherapy with platinum
derivatives in association with proton pump inhibitors and their correlation with
neuropathies. This is a randomized, double-blind clinical study. 164 patients
undergoing chemotherapy with regimens containing cisplatin or carboplatin were
included, checking the inclusion and exclusion criteria. The volunteers were
randomized into Lots 1 and 2 at a ratio of 1: 1, consecutively, in the groups using
cisplatin and carboplatin, batches were revealed only after the end of the study.
According to the data, there was a higher frequency of patients with head and neck
and lung cancer, for both groups. The mean age was 61.0 ± 12.5 for the placebo group
and 57.7 ± 14.3 for the PPI group, where the most frequent protocols were Carboplatin
plus Paclitaxel, followed by Cisplatin (Monotherapy). Regarding hypomagnesemia, a
tendency to decrease serum magnesium levels was highlighted in both groups (β = -
0.035; p <0.001), especially in those patients with preserved renal function (β = -0.414;
p <0.001 ). There was a more pronounced decrease in serum magnesiumIn in the
omeprazole group compared to the placebo (β = -0.121; p = 0.031). There was no
difference in the occurrence of clinical manifestations of the gastrointestinal tract and
neuropathy, however, the use of omeprazole caused less nausea and vomiting (p =
0.005). The results of the study showed a trend of hypomagnesemia in both groups,
with a greater hypomagnesemia in the intervention group, but without significant
difference in the reactions evaluated. The group of platinum associated with
omeprazole suggests a benefit in the association as prevention of nausea and
vomiting.


BANKING MEMBERS:
Externo à Instituição - MARIO JORGE SOBREIRA DA SILVA - INCA
Externa à Instituição - MARIANA MARTINS GONZAGA DO NASCIMENTO - UFMG
Presidente - 1201781 - FERNANDA NERVO RAFFIN
Externa ao Programa - 3315645 - FRANCISCA SUELI MONTE MOREIRA
Externa à Instituição - Margareth de Fátima Formiga Melo Diniz - UFPB
Notícia cadastrada em: 22/06/2021 10:13
SIGAA | Superintendência de Tecnologia da Informação - (84) 3342 2210 | Copyright © 2006-2024 - UFRN - sigaa12-producao.info.ufrn.br.sigaa12-producao